Korean aesthetic device company reported on Wednesday the receipt of the US Food and Drug Administration's 510 (K) clearance to market WONTECH SANDRO DUAL laser device across the global markets, including the US and Europe.
Recently, the SANDRO DUAL was launched in Korea Nd:YAG & Alexandrite based lasers mounted on one device.
According to the company, the SANDRO DUAL can be implemented in the hybrid mode in a short time difference between two wavelengths of 755nm and 1064nm. The energy is accurately delivered to a specific area to deliver an effective and quick treatment in hair removal as well as whitening without damaging surrounding tissue.
In addition, the the SANDRO DUAL's SCS (Skin Cooling Spray) cooling system minimizes patient discomfort from pain, swelling and redness.
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
FDA accepts Xspray Pharma's NDA for XS003 with PDUFA date set for June 2026
Citius Oncology and McKesson sign US distribution agreement for LYMPHIR
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Antengene reveals ATG-022 clinical data at ESMO 2025
WeightWatchers launches RxFlexFund to expand affordable GLP-1 access for employers and employees
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study